Literature DB >> 12040682

[Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin].

Maki Murakami1, Akio Morikawa, Ryugo Okabe, Ken Hayashi, Koichi Miyazawa, Satoshi Iijima, Kazunori Ozaki, Akira Suzuki, Yoshinori Koyama, Atsushi Sugiyama.   

Abstract

We report three patients with recurrent gastric cancer responding to TS-1 therapy after combination chemotherapy with 5-fluorouracil, mitomycin C and cisplatin. All 3 cases had undergone total gastrectomy with lymphadenectomy for advanced gastric cancer. Postoperative follow-up computed tomography (CT) showed liver metastases (cases 1 and 3), peritoneal dissemination (case 2) and enlargement of paraaortic lymph nodes (case 1) due to cancer recurrence. After 2 to 4 courses of combined treatment with 5-fluorouracil (500-750 mg/body/day, days 1-5, civ), mitomycin C (6-8 mg/body, day 6) and cisplatin (60-80 mg/body, day 7), CT revealed considerable reduction of the metastatic tumors. Subsequently oral administration of TS-1 (80-100 mg/body/day) for 4 weeks was performed. All 3 patients are well without any signs of increase in tumor size.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12040682

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

Review 1.  Management strategies for locoregional recurrence in early-stage gastric cancer: retrospective analysis and comprehensive literature review.

Authors:  Ahmed Salem; Sameh Hashem; Layth Y I Mula-Hussain; Issa Mohammed; Ala'a Nour; Wael Shelpai; Faiez Daoud; Basem Morcos; Yasser Yamin; Imad Jaradat; Jamal Khader; Abdelatief Almousa
Journal:  J Gastrointest Cancer       Date:  2012-03

2.  Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer.

Authors:  Mi-Sook Kim; Sung Yul Yoo; Chul Koo Cho; Hyung Jun Yoo; Kwang Mo Yang; Jin Kyu Kang; Dong Han Lee; Jong Inn Lee; Ho Youn Bang; Min Suk Kim; Hae Jin Kang
Journal:  J Korean Med Sci       Date:  2009-06-16       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.